| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
Physostigmine salicylate (AR-44; CCRIS-3405) is a potent and reversible cholinesterase inhibitor and a parasympathomimetic alkaloid. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
| ln Vivo |
To enhance threat memory and cue memory impairments in Tg(+) mice, physostigmine salicylate (also known as Eserine salicylate; 0.03-0.3 mg/kg; sc; once daily for 6 weeks) is administered [2].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Heterozygous transgenic mice (Tg(+) mice)[2]
Doses: 0.03, 0.1 and 0.3 mg/kg Route of Administration: SC; one time/day for 6 weeks Experimental Results: Tg(+) Animal Situation Memory deficits normalized, causing them to become more similar to Tg(-) animals. |
| References |
|
| Additional Infomation |
Crystal form that turns red on exposure to heat or light. (EPA, 1998)
Physostigmine salicylate is an azaheterocycle salicylate salt and a member of salicylates. It contains a physostigmine. See also: Physostigmine (has active moiety). |
| Molecular Formula |
C22H27N3O5
|
|---|---|
| Molecular Weight |
413.46688
|
| Exact Mass |
413.195
|
| CAS # |
57-64-7
|
| Related CAS # |
Physostigmine hemisulfate;64-47-1;Physostigmine;57-47-6
|
| PubChem CID |
657348
|
| Appearance |
White to yellow solid powder
|
| Boiling Point |
393.5ºC at 760 mmHg
|
| Melting Point |
181-183 °C
|
| Flash Point |
191.8ºC
|
| LogP |
3.258
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
30
|
| Complexity |
535
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C.C1=CC=C(C(=C1)C(=O)O)O
|
| InChi Key |
HZOTZTANVBDFOF-PBCQUBLHSA-N
|
| InChi Code |
InChI=1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-28-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)1-4,8H,(H,9,10)/t13-,15+/m1./s1
|
| Chemical Name |
Benzoic acid, 2-hydroxy-, compd. with
(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl
methylcarbamate (1
|
| Synonyms |
Physostigmine salicylate Antilirium AR-44 CCRIS
3405 EINECS 200-343-8 Isopto Eserine Physostigmine monosalicylate.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~302.32 mM)
H2O : ~33.33 mg/mL (~80.61 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5 mg/mL (12.09 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4186 mL | 12.0928 mL | 24.1856 mL | |
| 5 mM | 0.4837 mL | 2.4186 mL | 4.8371 mL | |
| 10 mM | 0.2419 mL | 1.2093 mL | 2.4186 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
